Skip to main content
Equibles
PRCT logo

PRCT · PROCEPT BioRobotics Corp · Metrics

Track PRCT — free

Use PRCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.82 +0.00 (+0.00%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.08B
Shares
57.27M
Volume · Oct 20 985.6K Avg daily vol (3M) 1.41M

PRCT metrics

92 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$18.82
Market cap
$1.08B

Price action

20 metrics
Price change (1W)
-1.5%
Price change (30D)
+1.7%
Price change (3M)
+1.6%
Price change (6M)
-24.0%
Price change (YTD)
-40.2%
Price change (1Y)
-45.8%
Trailing year
Price change (5Y)
-56.3%
52-week high
$36.95
52-week low
$16.69
Change from 52-week high
-49.1%
Change from 52-week low
+12.8%
Annualized volatility
64.6%
Annualized volatility (3M)
59.7%
Beta
0.8
RSI (14D)
51.5
Price vs SMA 50
-4.5%
Price vs SMA 200
-21.1%
Avg volume (3M)
1.41M
Relative volume
0.7
Average dollar volume
$27.16M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
57.27M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.6×
reciprocal yield 38.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
3.1×
reciprocal yield 32.2%
P / book
3.1
reciprocal yield 32.5%
FCF yield
-8.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
11.3×
reciprocal yield 8.9%
EV / revenue historical average (5Y)
15.3×
reciprocal yield 6.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
64.2%
Operating margin
-33.9%
Trailing 12 months
Net margin
-32.5%
Gross profit (TTM)
$216.65M
Operating profit (TTM)
−$114.23M
Net income (TTM)
−$109.76M
Trailing 12 months
Diluted EPS (TTM)
$-1.95
FCF margin
-25.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$5.98
Gross profit per diluted share (TTM)
$3.84
Operating profit per diluted share (TTM)
$-2.03
EBITDA per diluted share (TTM)
$-1.90
Net income per diluted share (TTM)
$-1.95
Operating cash flow per diluted share (TTM)
$-1.32
Free cash flow per diluted share (TTM)
$-1.50
Capital expenditures per diluted share (TTM)
$0.19
R&D per diluted share (TTM)
$1.40
Stock compensation per diluted share (TTM)
$0.94
Book value per share
$6.50

Growth

11 metrics
Revenue growth YoY
+19.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$337.34M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.9%
Year over year · more shares
Revenue CAGR (3Y)
+60.1%
Revenue CAGR (5Y)
+109.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-32.3%
Return on assets
-22.9%
Debt / equity
0.2
Current ratio
6.5
EBITDA (TTM)
−$107.18M
Free cash flow (TTM)
−$84.92M
Quick ratio
5.3
Interest coverage
-32.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$176.20M
Latest balance sheet
Cash & equivalents
$227.91M
Total assets
$479.35M
Total debt
$51.72M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$74.34M
Capital expenditures (TTM)
$10.59M
R&D (TTM)
$78.81M
SG&A (TTM)
$252.06M
Stock compensation (TTM)
$52.94M
R&D / revenue
23.4%
Stock compensation / revenue
15.7%

Ownership (13F)

9 metrics
13F filers
256
13F filer change QoQ
-3
Institutional ownership
97.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
24.5%
Private-fund adviser ownership
21.1%
Active holders' share change QoQ
-3.0%
Holder tenure
10.1
Price vs estimated holder cost
-39.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
18.1%

Short interest

3 metrics
Short interest
13.0%
Latest settlement · 5.3 days to cover
Days to cover
5.3d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
$476,461
Insider-sentiment score
67 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1588978 CUSIP 74276L105 13F (30d) 23 filings 23 filers Visit website Investor relations